Find clinical trials for AstraZeneca. Search for AstraZeneca clinical trials in different cities and states across the United States.
Filter
Filter results
Results: 139
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: New Haven CT, Brooklyn NY, New York NY, Montreal,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06350097
Phase 3, Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Location: New York NY, Philadelphia PA, Ottawa, Toronto,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06526793
Phase 2, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: St. John's, Rimouski, Boston MA, Levis, Stony Brook NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase 3, Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
for
Multiple Myeloma
Location: Boston MA, New York NY, Montreal, Philadelphia PA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06106945
Phase 1, Phase 2, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: Saint John, South Portland ME, West Haven CT,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
for
Carcinoma, Non-Small Cell Lung
Location: Westbury NY, Fresh Meadows NY, Philadelphia PA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06868277
Phase 3, Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
for
Locally Advanced Cervical Cancer
Location: Montreal, Toronto, Hamilton
Sponsor: AstraZeneca
Sex: Female
Age: 15+
Code: NCT06079671
Phase 3, Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
for
Hyperkalaemia
Location: Montreal, Baltimore MD, Columbia SC, Cincinnati OH,
Sponsor: AstraZeneca
Sex: All
Age: 0 - 18
Code: NCT03813407
Phase 3, Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
for
Heart Failure and Impaired Kidney Function
Location: Sydney, Boston MA, Providence RI, The Bronx NY,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06307652
Phase 3, Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
for
Polymyositis, Dermatomyositis
Location: Boston MA, New Haven CT, Great Neck NY, Montreal,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06455449
Phase 3, Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
for
Breast Cancer
Location: Providence RI, New Haven CT, Quebec, Stony Brook NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06103864
Phase 3, Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
for
Viral Lung Infection and Acute Respiratory Failure
Location: Levis, Quebec, New York NY, Montreal, Annapolis MD,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05624450
Phase 3, Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
for
Chronic Kidney Disease and Hypertension
Location: Halifax, Saint John, New Bedford MA, Braintree MA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06742723
Phase 3, Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
for
Lupus Erythematosus, Systemic
Location: Boston MA, New York NY, Syracuse NY, Chapel Hill NC,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70
Code: NCT06897930
Phase 1, Phase 2, Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
for
Endometrial Cancer
Location: Boston MA, Providence RI, Lebanon NH, Quebec,
Sponsor: AstraZeneca
Sex: Female
Age: 18+
Code: NCT06989112
Phase 3, Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
for
Advanced Solid Malignancies
Location: Boston MA, New York NY, Chicago IL, Houston TX,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT05417594
Phase 1, Phase 2, Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
for
Heart Failure
Location: St. John's, Sydney, Halifax, Moncton, Saint John,
Sponsor: AstraZeneca
Sex: All
Age: 40+
Code: NCT06677060
Phase 3, Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
for
COPD (Chronic Obstructive Pulmonary Disease)
Location: Sydney, Boston MA, Quebec, Massapequa NY, The Bronx NY,